With heating interest in the obesity drug Wegovy, the way-around measures the consumers are taking to receive prescriptions are causing controversy.

From how to receive Wegovy through non-face-to-face treatment venues without the legwork to how to split the high-dose formulations being shared online, concerns are growing over the drug’s misuse.

The first issue is non-qualified prescriptions. Prescriptions that ignore the prescribing criteria, such as obese patients with a body mass index (BMI) of 30 kg/m2 or more, are becoming widespread, and one of the outlets for such is the non-face-to-face treatment platforms.

As influencers with tens of thousands to hundreds of thous